Rubicon Research Limited Share Price & Analysis
₹1,516.9▲ +0.34%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹1,516.9
+0.34%
Open
₹—
High
₹1,539
Low
₹1,485.4
Close
₹1,516.9
52W High
₹1,527
52W Low
₹571
Volume
263K
Lot Size
1
Sector
Healthcare
Market Cap
₹24K Cr
Face Value
₹1
Large Cap
Price Chart
Fundamentals
P/E
96.5
Sector P/E
54.4
P/B
31.05
EPS
₹15.34
ROE
27%
ROCE
28.4%
D/E Ratio
0.88
Div Yield
0%
Book Value
₹78.1
+
Strengths
- ✓Excellent return on equity (ROE 27%)
- ✓Efficient capital deployment (ROCE 28.4%)
−
Concerns
- ✗Premium to sector peers (P/E 96.5x vs industry 54.4x)
- ✗High premium to book value (P/B 31.1x)
- ✗Trading near 52-week high (₹1,527)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹514 Cr ▲8.0% | ₹476 Cr ▲15.5% | ₹412 Cr ▲17.0% | ₹352 Cr ▼1.7% | ₹358 Cr ▲14.4% | ₹313 Cr ▲5.7% | ₹296 Cr |
| Op. Profit | ₹119 Cr ▲10.2% | ₹108 Cr ▲14.9% | ₹94 Cr ▲19.0% | ₹79 Cr ▲9.7% | ₹72 Cr ▲2.9% | ₹70 Cr ▲12.9% | ₹62 Cr |
| OPM | 23.0% ▲0.0% | 23.0% ▲0.0% | 23.0% ▲4.5% | 22.0% ▲10.0% | 20.0% ▼9.1% | 22.0% ▲4.8% | 21.0% |
| Net Profit | ₹77 Cr ▲5.5% | ₹73 Cr ▲35.2% | ₹54 Cr ▲25.6% | ₹43 Cr ▲19.4% | ₹36 Cr ▼5.3% | ₹38 Cr ▲11.8% | ₹34 Cr |
| EPS (₹) | 4.65 ▲5.2% | 4.42 ▲26.6% | 3.49 ▲24.2% | 2.81 ▲19.6% | 2.35 ▼6.0% | 2.5 ▲10.1% | 2.27 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹1.8K Cr ▲36.6% | ₹1.3K Cr ▲50.4% | ₹854 Cr ▲116.8% | ₹394 Cr ▲25.5% | ₹314 Cr ▼0.3% | ₹315 Cr ▲19.8% | ₹263 Cr |
| Expenses | ₹1.4K Cr ▲31.7% | ₹1.0K Cr ▲47.1% | ₹699 Cr ▲86.4% | ₹375 Cr ▲6.2% | ₹353 Cr ▲58.3% | ₹223 Cr ▲22.5% | ₹182 Cr |
| Op. Profit | ₹400 Cr ▲56.3% | ₹256 Cr ▲65.2% | ₹155 Cr ▲761.1% | ₹18 Cr ▲146.2% | ₹-39 Cr ▼142.4% | ₹92 Cr ▲13.6% | ₹81 Cr |
| OPM | 23.0% ▲15.0% | 20.0% ▲11.1% | 18.0% ▲260.0% | 5.0% ▲141.7% | -12.0% ▼141.4% | 29.0% ▼6.5% | 31.0% |
| Other Income | ₹8 Cr ▼33.3% | ₹12 Cr ▼33.3% | ₹18 Cr ▼28.0% | ₹25 Cr ▲47.1% | ₹17 Cr ▲70.0% | ₹10 Cr ▼44.4% | ₹18 Cr |
| Interest | ₹42 Cr ▲13.5% | ₹37 Cr ▲19.4% | ₹31 Cr ▲63.2% | ₹19 Cr ▲90.0% | ₹10 Cr ▲11.1% | ₹9 Cr ▲50.0% | ₹6 Cr |
| Depreciation | ₹45 Cr ▲21.6% | ₹37 Cr ▼5.1% | ₹39 Cr ▲8.3% | ₹36 Cr ▲5.9% | ₹34 Cr ▲17.2% | ₹29 Cr ▲61.1% | ₹18 Cr |
| PBT | ₹321 Cr ▲64.6% | ₹195 Cr ▲89.3% | ₹103 Cr ▲1036.4% | ₹-11 Cr ▲83.3% | ₹-66 Cr ▼204.8% | ₹63 Cr ▼14.9% | ₹74 Cr |
| Tax % | 23.0% ▼25.8% | 31.0% ▲158.3% | 12.0% ▼77.4% | 53.0% ▲2550.0% | 2.0% ▼96.1% | 51.0% ▲54.5% | 33.0% |
| Net Profit | ₹247 Cr ▲84.3% | ₹134 Cr ▲47.3% | ₹91 Cr ▲635.3% | ₹-17 Cr ▲74.6% | ₹-67 Cr ▼316.1% | ₹31 Cr ▼36.7% | ₹49 Cr |
| EPS (₹) | 14.95 ▲71.4% | 8.72 ▲45.8% | 5.98 ▲118.0% | -33.31 ▲74.8% | -132.39 ▼318.7% | 60.53 ▼37.9% | 97.46 |
| Div Payout | 10.0% | 0.0% | 0.0% ▲100.0% | -2.0% | 0.0% ▼100.0% | 2.0% ▲0.0% | 2.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Liabilities | |||||||
| Equity Capital | ₹17 Cr ▲13.3% | ₹15 Cr ▲0.0% | ₹15 Cr ▲200.0% | ₹5 Cr ▲0.0% | ₹5 Cr ▲0.0% | ₹5 Cr ▲0.0% | ₹5 Cr |
| Reserves | ₹1.3K Cr ▲141.8% | ₹526 Cr ▲42.2% | ₹370 Cr ▲31.7% | ₹281 Cr ▼6.3% | ₹300 Cr ▼18.7% | ₹369 Cr ▲10.1% | ₹335 Cr |
| Borrowings | ₹311 Cr ▼25.6% | ₹418 Cr ▼1.6% | ₹425 Cr ▲32.8% | ₹320 Cr ▲82.9% | ₹175 Cr ▲88.2% | ₹93 Cr ▲210.0% | ₹30 Cr |
| Other Liabilities | ₹727 Cr ▲47.5% | ₹493 Cr ▲64.3% | ₹300 Cr ▲108.3% | ₹144 Cr ▲82.3% | ₹79 Cr ▲11.3% | ₹71 Cr ▲18.3% | ₹60 Cr |
| Total Liabilities | ₹2.3K Cr ▲60.4% | ₹1.5K Cr ▲30.8% | ₹1.1K Cr ▲47.9% | ₹750 Cr ▲33.9% | ₹560 Cr ▲4.1% | ₹538 Cr ▲25.1% | ₹430 Cr |
| Assets | |||||||
| Fixed Assets | ₹532 Cr ▲62.7% | ₹327 Cr ▲6.5% | ₹307 Cr ▲54.3% | ₹199 Cr ▲3.1% | ₹193 Cr ▲2.7% | ₹188 Cr ▲19.7% | ₹157 Cr |
| CWIP | ₹40 Cr ▲471.4% | ₹7 Cr ▼30.0% | ₹10 Cr ▼60.0% | ₹25 Cr ▲733.3% | ₹3 Cr ▼50.0% | ₹6 Cr ▲200.0% | ₹2 Cr |
| Investments | ₹27 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr ▼100.0% | ₹14 Cr ▼26.3% | ₹19 Cr |
| Other Assets | ₹1.7K Cr ▲54.6% | ₹1.1K Cr ▲41.0% | ₹793 Cr ▲50.8% | ₹526 Cr ▲44.5% | ₹364 Cr ▲10.3% | ₹330 Cr ▲31.0% | ₹252 Cr |
| Total Assets | ₹2.3K Cr ▲60.4% | ₹1.5K Cr ▲30.8% | ₹1.1K Cr ▲47.9% | ₹750 Cr ▲33.9% | ₹560 Cr ▲4.1% | ₹538 Cr ▲25.1% | ₹430 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Operating CF | ₹205 Cr ▲28.9% | ₹159 Cr ▲657.1% | ₹21 Cr ▲128.0% | ₹-75 Cr ▼19.0% | ₹-63 Cr ▼201.6% | ₹62 Cr ▲1140.0% | ₹5 Cr |
| Investing CF | ₹-410 Cr ▼530.8% | ₹-65 Cr ▲4.4% | ₹-68 Cr ▼112.5% | ₹-32 Cr ▲30.4% | ₹-46 Cr ▲0.0% | ₹-46 Cr ▲45.2% | ₹-84 Cr |
| Financing CF | ₹283 Cr ▲807.5% | ₹-40 Cr ▼190.9% | ₹44 Cr ▼64.2% | ₹123 Cr ▲95.2% | ₹63 Cr ▲21.2% | ₹52 Cr ▼35.0% | ₹80 Cr |
| Net Cash Flow | ₹78 Cr ▲44.4% | ₹54 Cr ▲1450.0% | ₹-4 Cr ▼125.0% | ₹16 Cr ▲135.6% | ₹-45 Cr ▼167.2% | ₹67 Cr ▲6600.0% | ₹1 Cr |
| Free Cash Flow | ₹-24 Cr ▼126.4% | ₹91 Cr ▲360.0% | ₹-35 Cr ▲70.6% | ₹-119 Cr ▼1.7% | ₹-117 Cr ▼1070.0% | ₹-10 Cr ▲81.5% | ₹-54 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 106d ▲15.2% | 92d ▼28.7% | 129d ▼38.3% | 209d ▲29.0% | 162d ▲2.5% | 158d ▼18.6% | 194d |
| Inventory Days | 479d ▼16.6% | 574d ▲34.1% | 428d ▼29.7% | 609d ▲21.3% | 502d ▼1.2% | 508d ▲41.1% | 360d |
| Days Payable | 248d ▼5.7% | 263d ▲4.4% | 252d ▼28.6% | 353d ▲10.3% | 320d ▲18.1% | 271d ▲48.1% | 183d |
| Cash Conv. Cycle | 337d ▼16.4% | 403d ▲32.1% | 305d ▼34.4% | 465d ▲34.8% | 345d ▼12.7% | 395d ▲6.5% | 371d |
| Working Capital Days | 104d ▲126.1% | 46d ▼19.3% | 57d ▼24.0% | 75d ▼29.9% | 107d ▼28.2% | 149d ▼18.6% | 183d |
| ROCE | 28.0% ▲7.7% | 26.0% ▲36.8% | 19.0% ▲1800.0% | 1.0% ▲108.3% | -12.0% ▼170.6% | 17.0% | — |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Rubicon Research Limited share price today?▾
Rubicon Research Limited (RUBICON) is currently trading at ₹1,516.9 on NSE, up 0.34% as of the last market session. Prices update daily after market close on MarketNetra.
Is Rubicon Research Limited available in F&O (Futures & Options)?▾
Yes, Rubicon Research Limited (RUBICON) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Rubicon Research Limited 52-week high and low?▾
Rubicon Research Limited's 52-week high is ₹1,527 and the 52-week low is ₹571. The current price of ₹1,516.9 is 0.7% below the 52W high.
What is Rubicon Research Limited P/E ratio?▾
Rubicon Research Limited's current P/E ratio is 96.5. This indicates the market is paying ₹96.5 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Rubicon Research Limited options?▾
Rubicon Research Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade RUBICON options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.